Preamble
The book is based on a Symposium organised by the Association of Medical Advisers to the Pharmaceutical Industry held at the Royal College of Physicians on 6th and 7th May 1976. The details of the book that arose from the first Symposium are presented at no. (22) above.

Aims
This book is intended for use by medical advisers in the pharmaceutical industry and clinicians who are involved in the evaluation of drugs. It is designed mainly for those new to the field, as was the first edition, but it also contains much useful information for those with experience who wish to improve their knowledge or expand their interest. The highly successful first edition went out of print last year. Many aspects had changed since it was published. Therefore a fresh symposium with the same title was held again at the Royal College of Physicians, to bring the material up to date. The further developments in clinical trials to which this book pays particular attention are: the rapidly increasing costs of trials, and how to budget for them; the increasing complexity of statutory legislation; the somewhat arbitrary division of clinical trials into phases I to IV; the great increase in attempts to monitor adverse reactions and the development of drug surveillance programmes; the advances in data handling and statistical analysis (Preface, page vii).

Contents (xii+201 pages)
Foreword (Sir Cyril Clarke)
Preface (CS Good)
List of contributors
Part 1: Setting up clinical trials
  1. Ethics of clinical trials (DW Vere)
  2. Regulations relating to clinical trials (MF Cuthbert)
  3. Volunteer studies and human pharmacology – phase I (IM James)
  4. Clinical trials – phases II, III and IV (RB Smith)
    Discussion Part 1
Part 2: Setting-up clinical trials (continued)
  5. Designing the correct protocol (DM Burley)
  6. Designing the report form (F Grady)
  7. The choice of investigator (ES Snell)
  8. Budgeting for clinical trials (PA Nicholson)
  9. Statistical aspects of trial design (KD MacRae)
    Discussion Part 2
Part 3: The running and evaluation of clinical trials
  1. Getting the trial of the ground: logistics, presentation of supplies (AW Galbraith)
  2. Keeping the trial going: medical advisers or coordinators: prescription costs (BT Marsh)
  3. Adverse reaction monitoring (AW Harcus)
  4. Handling data and trial results (F Grady)
  5. Statistical analysis of trial results (JJ Grimshaw)
  6. Presentation of results (CF Hawkins)
    Discussion Part 3
Part 4: Model specimens of clinical trials: criteria
7. Anti-anginal trials (TDV Lawrie, WS Hillis, A Tweddel)
8. Clinical trials of antibiotics (DS Reeves)
9. The designing of oral contraceptive trials (PGT Bye)
10. Antidepressant and anxiolytic trials (G Beaumont)
11. Trials of anti-rheumatic drugs (EC Huskisson)

Discussion Part 4

Index

Authors

The Editor is CS Good MA, BM, BCh, FRCS, (Senior Medical Adviser in the Pharmaceuticals Division of Bayer UK Ltd); the foreword is by Sir Cyril Clarke KBE, MD, PRCP, FRS (President of the Royal College of Physicians, London). The Chairmen are Dr G Beaumont MB, ChB, DOBST, RCOG, DCH (Chairman of AMAPI and Medical Adviser, Geigy Pharmaceuticals, Macclesfield), Professor TDV Lawrie MD, FRCP (Edin & Glas) (Walton professor of Medical Cardiology, Royal Infirmary, Glasgow); and Dr PA Nicholson MB, BS (Medical Director, Hoechst UK Ltd, Pharmaceutical Division, Hounslow). The other contributors are DM Burley MB, BS, MRCS (Head of Medical Services, CIBA laboratories, Horsham); PGT Bye BA, MB, BCHIR, DCH (Senior Medical Adviser, Schering Chemicals Ltd, Burgess Hill); MF Cuthbert MB, BS, PhD (Principal Medical Officer, Medicines Division, Department of Health and Social Security, London); AW Galbraith MA, MB, BCHIR, DOBST, RCOG, DCH (General Practitioner, London); F Grady (Data Services Section, Imperial Chemical Industries Ltd, Macclesfield); JJ Grimshaw BSc, FIS (Consultant Statistician, Wessex Consultancy, Aldershot); AW Harcus MB, ChB, DOBST, RCOG (Medical Director, Reckitt and Colman, Kingston-upon-Hull); CF Hawkins MD, FRCP (Consultant Physician to the Central Birmingham Health District, The Queen Elizabeth Hospital, Birmingham); WS Hillis MB, MRCP (Senior Registrar in Cardiology, University Department of Medical Cardiology, Royal Infirmary, Glasgow); EC Huskisson MD, MRCP (Consultant Physician, St Leonard’s Hospital, London, and Senior Lecturer, Medical College of St Bartholomew’s Hospital, London); IM James MRCP, MB, BS, PhD (Senior Lecturer in Medicine and Therapeutics, Medical Unit, The Royal Free Hospital, London); KD MacRae MA, PhD (Senior Lecturer in Statistics, Charing Cross Hospital Medical School, London); BT Marsh MB, BS, DOBST, RCOG (Medical Director, Leo Laboratories Ltd, Hayes, Middlesex); DS Reeves MB, MRCPATH (Consultant Medical Microbiologist, Department of Medical Microbiology, Southmead General Hospital, Bristol); RB Smith BSc, MD (Research and Development Director, Reckitt and Colman, Kingston-upon-Hull); ES Snell MA, MD, FRCP (Director, Clinical Division, Glaxo Research Ltd, Greenford); AC Tweddel MB, ChB (Registrar in Cardiology, University Department of Medical Cardiology, Royal Infirmary, Glasgow); and, DW Vere MD, FRCP (Professor of Therapeutics, London Hospital Medical College, London).